We will develop, demonstrate, and evaluate a novel approach to assessing tumor oxygenation with a view to rapid translation to the clinic. We believe it will be most pertinent to high dose hypofractionated radiotherapy in diseases such as prostate cancer. DOCENT (Dynamic Oxygen Challenge Evaluated by NMR T1 and T2*) exploits BOLD (blood oxygen level dependent) and TOLD (tissue oxygen level dependent) contrast to non- invasively detect changes in tumor oxygenation using proton MRI. We propose to develop DOCENT as a robust prognostic test to reveal tumor hypoxia. Ever since the classic studies of Gray et al. fifty years ago, it has been appreciated that hypoxia can influence the efficacy of radiotherapy. There have been many attempts to modulate tumor hypoxia, but translation to the clinic has shown marginal efficacy. Hypoxia has been confirmed in human tumors and correlated with therapeutic outcome, but the current biopsy/histology, electrodes, and nuclear medicine imaging approaches are neither convenient nor widely used. Current radiotherapy uses extended fractionation regimens requiring patients to attend daily for many weeks. This is predicated on the need to avoid normal tissue damage. The development of highly focused beams and stereotactic body radiation therapy (SBRT) allows higher doses with a few fractions to be considered again. Hypoxia is likely to play a greater role for small numbers of high dose irradiations, since there is less opportunity for the inter fraction reoxygenation encountered between daily low doses. We have shown direct correlations between tumor growth delay following single high dose irradiation and pO2 in prostate tumors growing in rats based on 19F MR oximetry previously, but this required an exogenous reporter molecule. We believe that oxygen sensitive 1H MRI will allow us to identify hypoxic tumors based on tissue water relaxation alone and ultimately stratify patients for individualized hypoxia-dependant therapy. While the investigations proposed here are entirely pre-clinical, we believe they will demonstrate a strong rationale for rapid implementation in patients.
Aim 1 will rigorously demonstrate the ability of DOCENT to categorize tumors as hypoxic (resistant or responsive) or oxic by comparison with 19F MR oximetry.
Aim 2 will examine whether DOCENT does indeed predict response to hypofractionated radiation in subcutaneously growing prostate tumors.
Aim 3 will extend studies to orthotopic prostate tumors.
Aim 4 will seek to overcome therapeutic resistance of hypoxic tumors by including a radiation boost. This proposal responds to conclusions of a recent NCI-sponsored workshop to assess the current status of hypoxia imaging. There was consensus that a robust practical method is needed to identify patients with hypoxic tumors. Requisite criteria relate to invasiveness, radiation exposure, resolution, safety, and time to potential clinical implementation. A BOLD approach was considered to be particularly practical and the addition of the TOLD assessment can make it even more useful.

Public Health Relevance

We will develop, demonstrate, and evaluate a novel approach to assessing tumor oxygenation. DOCENT (Dynamic Oxygen Challenge Evaluated by NMR T1 and T2*) exploits BOLD (blood oxygen level dependent) and TOLD (tissue oxygen level dependent) approaches to non-invasively detect changes in tumor oxygenation using proton MRI. We propose to develop this as a robust prognostic test to reveal tumor hypoxia, which could become a valuable tool in stratifying patients for personalized therapy planning in diseases such as prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA139043-03
Application #
8204951
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Bernhard, Eric J
Project Start
2010-01-01
Project End
2014-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
3
Fiscal Year
2012
Total Cost
$319,272
Indirect Cost
$117,997
Name
University of Texas Sw Medical Center Dallas
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Belfatto, Antonella; White, Derek A; Mason, Ralph P et al. (2016) Tumor radio-sensitivity assessment by means of volume data and magnetic resonance indices measured on prostate tumor bearing rats. Med Phys 43:1275-84
White, Derek A; Zhang, Zhang; Li, Li et al. (2016) Developing oxygen-enhanced magnetic resonance imaging as a prognostic biomarker of radiation response. Cancer Lett 380:69-77
Hallac, Rami R; Zhou, Heling; Pidikiti, Rajesh et al. (2016) A role for dynamic contrast-enhanced magnetic resonance imaging in predicting tumour radiation response. Br J Cancer 114:1206-11
Zhao, Dawen; Pacheco-Torres, Jesús; Hallac, Rami R et al. (2015) Dynamic oxygen challenge evaluated by NMR T1 and T2*--insights into tumor oxygenation. NMR Biomed 28:937-47
Zhang, Zhongwei; Yuan, Qing; Zhou, Heling et al. (2015) Assessment of tumor response to oxygen challenge using quantitative diffusion MRI in an animal model. J Magn Reson Imaging 42:1450-7
Belfatto, Antonella; White, Derek A; Zhang, Zhongwei et al. (2015) Mathematical modeling of tumor response to radiation: radio-sensitivity correlation with BOLD, TOLD, ΔR1 and ΔR2* investigated in large Dunning R3327-AT1 rat prostate tumors. Conf Proc IEEE Eng Med Biol Soc 2015:3266-9
Zhang, Zhongwei; Hallac, Rami R; Peschke, Peter et al. (2014) A noninvasive tumor oxygenation imaging strategy using magnetic resonance imaging of endogenous blood and tissue water. Magn Reson Med 71:561-9
Hallac, Rami R; Zhou, Heling; Pidikiti, Rajesh et al. (2014) Correlations of noninvasive BOLD and TOLD MRI with pO2 and relevance to tumor radiation response. Magn Reson Med 71:1863-73
Gulaka, Praveen K; Rojas-Quijano, Federico; Kovacs, Zoltan et al. (2014) GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo. J Biol Inorg Chem 19:271-9
Yu, Jian-Xin; Hallac, Rami R; Chiguru, Srinivas et al. (2013) New frontiers and developing applications in 19F NMR. Prog Nucl Magn Reson Spectrosc 70:25-49

Showing the most recent 10 out of 15 publications